secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oruka Therapeutics, Inc. (ORKA)
CIK:        0000907654
Form:       8-K
Filed at:   2024-09-13T23:59:59+00:00
Accession:  0001213900-24-078549
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 5.03, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oruka raises $200M via PIPE; accelerates ORKA-001/002 clinical timelines
------------------------------------------------------------------------

- Gross proceeds of ~$200M from sale of common stock, preferred stock, and pre-funded warrants at $23.00 per common share.
- Cash runway extended through 2027; closing expected September 13, 2024.
- First-in-human dosing of ORKA-001 (IL-23p19 mAb) now expected Q1 2025; ORKA-002 (IL-17A/F mAb) expected Q3 2025.
- Preclinical data show ORKA-001 half-life >30 days in NHPs; data to be presented at EADV September 25-28.
- Pro forma shares outstanding expected to be ~55.1 million including all conversions and warrants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/907654/000121390024078549/0001213900-24-078549-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/907654/000121390024078549/ea0214439-8k_oruka.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-078549

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer